Skip to content
The Policy VaultThe Policy Vault

Tagrisso (osimertinib) — Medica

Non-Small Cell Lung Cancer – Locally Advanced, Unresectable (Stage III) Disease

Initial criteria

  • age ≥ 18 years
  • Patient has locally advanced, unresectable (stage III) disease
  • Patient has EGFR exon 19 deletion or exon 21 (L858R) substitution mutation as detected by an approved test
  • Patient has not had disease progression during or following platinum-based chemoradiation therapy (concurrent or sequential)

Approval duration

1 year